Somewhat Favorable News Coverage Somewhat Unlikely to Affect Intersect ENT (XENT) Stock Price
Media headlines about Intersect ENT (NASDAQ:XENT) have been trending somewhat positive recently, according to Accern. Accern identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intersect ENT earned a coverage optimism score of 0.20 on Accern’s scale. Accern also gave media coverage about the medical equipment provider an impact score of 44.3663516563967 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Here are some of the headlines that may have effected Accern Sentiment Analysis’s rankings:
- Zacks: Brokerages Anticipate Intersect ENT Inc (XENT) Will Announce Earnings of -$0.17 Per Share (americanbankingnews.com)
- Intersect ENT (XENT) Given Buy Rating at Guggenheim (americanbankingnews.com)
- Insider Selling: Intersect ENT Inc (XENT) General Counsel Sells 36,000 Shares of Stock (americanbankingnews.com)
- Intersect ENT (XENT) SINUVA Implant Receives FDA Approval – Nasdaq (nasdaq.com)
- By a nose: Peninsula company moves from nasal devices to drugs with latest approval (feeds.bizjournals.com)
Intersect ENT (NASDAQ XENT) opened at $32.10 on Monday. Intersect ENT has a 12-month low of $11.02 and a 12-month high of $34.40.
XENT has been the subject of a number of recent analyst reports. Bank of America raised their price objective on Intersect ENT from $33.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, September 11th. Zacks Investment Research lowered Intersect ENT from a “buy” rating to a “hold” rating in a research note on Wednesday, November 1st. Canaccord Genuity raised their price objective on Intersect ENT from $32.00 to $37.00 and gave the company a “buy” rating in a research note on Wednesday, September 13th. Northland Securities restated a “hold” rating and set a $25.00 price objective on shares of Intersect ENT in a research note on Friday, November 3rd. Finally, BidaskClub lowered Intersect ENT from a “buy” rating to a “hold” rating in a research note on Wednesday, December 6th. Five equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $33.38.
In other news, COO Richard E. Kaufman sold 13,639 shares of Intersect ENT stock in a transaction that occurred on Monday, September 25th. The stock was sold at an average price of $28.97, for a total value of $395,121.83. Following the completion of the transaction, the chief operating officer now owns 133,757 shares in the company, valued at approximately $3,874,940.29. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Jeryl L. Hilleman sold 12,833 shares of Intersect ENT stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $27.78, for a total value of $356,500.74. Following the completion of the transaction, the chief financial officer now owns 27,833 shares of the company’s stock, valued at approximately $773,200.74. The disclosure for this sale can be found here. In the last quarter, insiders sold 129,838 shares of company stock valued at $3,892,610. Insiders own 13.70% of the company’s stock.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Ratings for Intersect ENT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT and related companies with MarketBeat.com's FREE daily email newsletter.